玄胡索散通过下调粒细胞集落刺激因子抑制脾脏髓源抑制细胞分化发挥抗乳腺癌作用

目的:探讨玄胡索散抑制乳腺癌小鼠脾脏髓源抑制细胞(MDSC)分化的作用机制。方法:4～5周龄BALB/c雌性小鼠48只,其中6只为正常对照组,其他42只采用小鼠左侧第二对乳腺皮下脂肪垫接种4T1细胞构建乳腺癌荷瘤小鼠模型,分为粒细胞集落刺激因子(G-CSF)对照组、G-CSF敲减组、模型对照组、玄胡索散小剂量组、玄胡索散中剂量组、玄胡索散大剂量组和环磷酰胺组,每组6只。其中G-CSF对照组和G-CSF敲减组分别采用shRNA慢病毒转染联合嘌呤霉素构建相应4T1稳转细胞模型。各组造模48 h后,玄胡索散小剂量组、玄胡索散中剂量组、玄胡索散大剂量组分别按2、4、8 g·kg^-1·d^-1玄胡索散灌胃,每天一次;环磷酰胺组按30 mg/kg腹腔注射环磷酰胺,隔天一次;其他组给予等体积0.5%羟甲基纤维素纳。各组连续给药25 d。苏木精-伊红染色观察脾脏组织病理学改变,流式细胞术测定脾脏MDSC亚群比例,免疫荧光法检测脾脏CD11b、Ly6G共表达,酶联免疫吸附测定外周血G-CSF浓度。在体外,建立荷瘤小鼠脾脏与4T1稳转株共培养体系,玄胡索散(30μ...     

酪酸梭菌活菌散对支气管哮喘患儿辅助性T细胞17、调节性T细胞及其相关细胞因子和肠道菌群的影响

目的 探讨酪酸梭菌活菌散对支气管哮喘患儿辅助性T细胞17(Th17细胞)、调节性T细胞(Tr细胞)及其相关细胞因子和肠道菌群的影响。方法 选择2018年3月至2020年6月新乡医学院第三附属医院收治的97例支气管哮喘患儿为研究对象,根据治疗方法将患儿分为观察组(n=49)和对照组(n=48)。对照组患儿给予吸入用布地奈德混悬液、吸入用异丙托溴铵溶液和孟鲁司特钠颗粒治疗;在对照组治疗基础上,观察者组患儿给予酪酸梭菌活菌散治疗,2组患儿均治疗2个月。应用流式细胞仪检测2组患儿治疗前后Th17细胞和Tr细胞水平,并计算Th17细胞与Tr细胞的比值(Th17/Tr);采用酶联免疫吸附试验检测2组患儿治疗前后血清中白细胞介素-17(IL-17)、白细胞介素-10(IL-10)水平。使用儿童肺功能仪检测2组患儿治疗前后第1秒用力呼气容积(FEV₁)、FEV₁/用力肺活量(FVC)、呼气流量峰值(PEF)日变异率;分别于治疗前后收集并培养2组患儿新鲜粪便,观察肠道菌群分布情况。治疗期间观察2组患儿不良反应发生情况,治疗后评估患儿临床疗效;所有患儿治疗后随访...     

Further Survey of Aflatoxin M1 in Milk Powders by ELISA

A survey of AFM₁ residues in 58 commercial milk powder samples was carried out using an enzyme‐linked immunosorbent assay (ELISA) based on a monoclonal antibody against aflatoxin M₁ (AFM₁). The samples were collected from the USA (10), China (28), Italy (14), New Zealand (3) and Poland (3). The ELISA was performed without the need for clean‐up procedures. The data revealed that 4 (US), 21 (Chinese) and 1 (Polish) samples were positive for AFM₁, with an average of 95.5, 102.8 and 85.0 pg g^‐1 of the AFM₁respectively.     

注射用清开灵冻干粉体外抗菌活性研究

目的：研究注射用清开灵冻干粉对临床分离致病菌的体外抗菌活性。方法：注射用清开灵冻干粉与市售清开灵注射液作比较，采用二倍稀释法，测定注射用清开灵冻干粉浓缩液对临床分离的47株致病菌的最低抑菌浓度（MIC）及最低杀菌浓度（憾），观察注射用清开灵冻干粉体外抗菌活性。结果：对金葡菌、大肠埃希菌、铜绿假单孢菌、肺炎克雷伯菌，注射用清开灵冻干粉与市售清开灵注射液均显示出良好的体外抗菌活性，注射用清开灵冻干粉体外抗菌活性强于市售清开灵注射液。按药液稀释度计算，注射用清开灵冻干粉浓缩液对金葡菌、大肠埃希菌、铜绿假单孢菌、肺炎克雷伯菌的MIC和MBC分别为市售清开灵注射液的1／4-1／2。结论：注射用清开灵冻干粉对临床分离的致病菌，具有较好的抗菌活性，且略优于市售清开灵注射液。     

A comparative study of the proteolytic enzymes of Trypanosoma brucei, T. equiperdum, T. evansi, T. vivax, Leishmania tarentolae and Crithidia fasciculata

Four types of proteolytic activity were detected in the bloodstream form of each of the four Trypanosoma species: (i) HPAase, active on hide powder azure and detected on polyacrylamide gels containing denatured haemoglobin; (ii) AZCase, active on azocasein; (iii) type 1, active on the chromogenic peptide N-benzoyl-L-prolyl-L-phenylalanyl-L-arginine p-nitroanilide in the presence of dithiothreitol, and (iv) type 2, active against several nitroanilide derivatives in the absence of dithiothreitol. Studies of the pH optimum, dithiothreitol requirement and inhibitor sensitivities of the proteolytic activities suggested that: (a) HPAase and type 1 activities could be due to the same enzymes, probably a family of cysteine proteinases; (b) AZCase had some characteristics of a cysteine proteinase, but was not identical to HPAase, and (c) type 2 activity could be due to a serine proteinase. Procyclic T. brucei contained relatively low cysteine proteinase activities (HPAase, AZCase and type 1) but high type 2 activity. Their proteolytic enzymes thus were apparently more similar to those in Crithidia fasciculata and Leishmania tarentolae promastigotes than those in T. brucei bloodstream forms.     

Formoterol inhaled as dry powder or via pressurized metered-dose inhaler in a cumulative dose-response study

Formoterol administered by a dry-powder (DP) capsule inhaler was compared with a pressurized metered-dose inhaler (pMDI) with regard to bronchodilating and systemic effects. The study used a double-blind, crossover, double-dummy technique. Twelve patients with moderate reversible asthma in a stable phase were examined on two separate study days, and the inhalers were given in randomized order. After baseline measurements, increasing doses of formoterol were given at intervals of 75 min. FEV₁ and heart rate and tremor measurements were repeated after each dose, and the doses were 12 + 12 + 24 + 48 μg, giving a total dose of 96 μg. The peak expiratory flow rate (PEFR) was recorded in the morning before the first dose, after the last dose, and then repeatedly at home until 19 h after the last dose. There was an equal increase in ventilatory capacity at each dose level, independent of inhaler device. Repeated PEFR measurements after the last dose did not reveal any differences in duration of effect. There was a slight but statistically significant increase in heart rate and tremor after the highest doses of the DP formulation compared to the pMDI. These systemic effects can probably be explained by the reduced oral deposition of the aerosol caused by using a spacer. This study indicates that the DP and pMDI formulations of formoterol are equipotent in bronchodilation.     

Comparison of Bricanyl® Turbuhaler and Berotec® dry powder inhaler

Terbutaline (Bricanyl) 0.5 mg t.i.d. administered via Turbuhaler was compared with fenoterol (Berotec) 0.2 mg t.i.d. administered via Inhalator Ingelheim in 36 asthmatic children aged 7-12 years. The study was of an open crossover design with two randomly allocated treatment periods, each lasting 2 weeks. Forced expiratory volume in 1 s (FEV1) and forced vital capacity (FVC) were measured at clinic visits before study start and at the end of each treatment period. The patients recorded peak expiratory flow (PEF) before and after inhaler use, morning and evening. They also recorded asthma symptoms and number of extra inhalations. At the end of the study, children and parents were asked for inhaler preference. No differences between the treatments were found concerning the results of the lung function measurements at the clinic or at the PEF measurements at home. No differences were found between the treatments as regards asthma symptoms or number of extra inhalations. Two patients experienced mild side effects during fenoterol treatment, none during terbutaline treatment. Treatment with terbutaline in Turbuhaler was preferred by a majority of children and parents. In conclusion, in this group of asthmatic children, treatment with terbutaline administered via Turbuhaler was as efficacious as treatment with fenoterol administered via Inhalator Ingelheim. There was a clear preference in favour of the Turbuhaler.     

山药配方颗粒溶化性差的原因分析与解决策略

山药配方颗粒由山药饮片经水煎煮提取、分离、浓缩、干燥、制粒而成,具有调剂简单、使用方便、免煎易服等优势。然而,因山药富含淀粉与黏液质类成分,其提取物粉末与配方颗粒溶化性差,在5 min内难以完全溶化或分散,不溶物即使在水中静置24 h也难以完全溶散,影响了配方颗粒的质量评价与患者的服药心理。因此,通过研究山药提取物及其配方颗粒的溶化过程与机制,发现山药特殊的化学组成、高温提取过程中淀粉的变性及其与蛋白质等物质的复合、喷雾干燥过程中“衣膜”的收缩形成等因素综合叠加,最终形成“衣膜”包覆淀粉粒的特殊微观结构,是山药配方颗粒溶化性差的根本原因。基于课题组前期对粉体结构-性质-功能的研究,笔者提出采用粉体改性工艺改善山药配方颗粒溶化性的技术策略,并通过实验证明改性处理后的山药配方颗粒能在2 min内实现全部溶散,解决了该技术难题,可为其他类似品种的溶化性改善提供借鉴,推动中药配方颗粒产业的高质量发展。     

制备工艺对ATO超细粉体导电性能的影响

采用化学共沉淀法制备锑掺杂二氧化锡（ATO）超细导电粉体,研究了反应温度,滴定终点pH值,掺锑量及锻炼温度对粉体导电性的影响,并对实验结果进行了讨论。     

Topical Vancomycin Powder and Dilute Povidone-Iodine Lavage Reduce the Rate of Early Periprosthetic Joint Infection After Primary Total Knee Arthroplasty

BackgroundVancomycin powder and dilute povidone-iodine lavage (VIP) was introduced to reduce the incidence of periprosthetic joint infection (PJI) in high-risk total knee arthroplasty (TKA) patients. We hypothesize that VIP can reduce the incidence of early PJI in all primary TKA patients, regardless of preoperative risk.MethodsAn infection database of primary TKAs performed before a VIP protocol was implemented (January 2012-December 2013), during a time when only high-risk TKAs received VIP (January 2014-December 2015), and when all TKAs received VIP (January 2016-September 2019) at an urban, university-affiliated, not-for-profit orthopedic hospital was retrospectively reviewed to identify patients with PJI. Criteria used for diagnosis of PJI were the National Healthcare Safety Network and Musculoskeletal Infection Society guidelines.ResultsVIP reduced early primary TKA PJI incidence in both the high-risk and all-risk cohorts compared with the pre-VIP cohort by 44.6% and 56.4%, respectively (1.01% vs 0.56% vs 0.44%, P = .0088). In addition, after introducing VIP to all-risk TKA patients, compared with high-risk TKA patients, the relative risk of PJI dropped an additional 21.4%, but this finding did not reach statistical significance (0.56% vs 0.44%, P = .4212). There were no demographic differences between the 3 VIP PJI cohorts.ConclusionVIP is associated with a reduced early PJI incidence after primary TKA, regardless of preoperative risk. With the literature supporting its safety and cost-effectiveness, VIP is a value-based intervention, but given the nature of this historical cohort study, a multicenter randomized controlled trial is underway to definitively confirm its efficacy.